We intend to focus our search for prospects within the insurance industry, including insurance tech (InsurTech) companies and  traditional insurance or insurance services companies.

  We are a clinical-stage biopharmaceutical company focused on developing next-generation viral immunotherapies to transform outcomes for cancer patients. Using our two distinct proprietary platforms, we are developing a pipeline of intratumorally and intravenously administered product candidates designed to selectively attack and kill tumor cells and stimulate multiple arms of the immune system against tumors.  […]

We intend to focus our search for a suitable initial business combination target in the next-generation mobility, transportation and sustainable industrial technology sectors, but we may pursue an initial business combination target in any stage of its corporate evolution or in any industry, sector or geographic location. Barry Engle, our chief executive officer, and Sam […]

(Note: GRAIL, Inc., withdrew its IPO plans on Aug. 23, 2021, following completion of its acquisition on Aug. 18, 2021, by Illumina. The U.S. Federal Trade Commission is challenging the acquisition and the matter is set to go to trial today – Aug. 24, 2021, at the FTC. This case marks the first “vertical” trial […]

This is a new blank check company led by Brenton L. Saunders, the former CEO of Allergan plc, best known for Botox, its wrinkle erasing product. From the prospectus: “We intend to focus on the pharmaceuticals and healthcare sectors with an emphasis on companies in the medical aesthetics, eye care, longevity and wellness categories.  “Our […]

This new blank check company intends to invest in clean energy businesses. Mary Powell, the retired CEO of Green Mountain Power, will be the chairperson of our board. David Crane, the former CEO of NRG Energy, is our CEO. PIMCO is a co-sponsor of the company. From the prospectus: “Climate change is the foundational issue […]

We are a biopharmaceutical company focused on harnessing the body’s natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins to treat cancer, neurodegenerative conditions and other diseases. We leverage our proprietary technology platform called TORPEDO (Target ORiented ProtEin Degrader Optimizer) to synthesize a new class of small molecule protein degraders that are […]

  While we may pursue an acquisition in any business industry or sector, we intend to concentrate our efforts on identifying businesses in the leisure, gaming and hospitality industries with an enterprise value exceeding $750 million, with particular emphasis on businesses that are well-positioned for growth. Our chairman, Bradley Tusk, is a venture capitalist (Tusk  Ventures) and […]

  We intend to capitalize on the ability of our management team and the broader Vector Capital platform to identify, acquire, and operate a business in the technology and technology-enabled services sectors that may provide opportunities for attractive long-term risk-adjusted returns, though we reserve the right to pursue an acquisition opportunity in any business or […]

  FinTech Acquisition Corp. IV is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, which we refer to throughout this prospectus as our initial business combination. We have not selected any business combination target […]